Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 2
1950 2
1951 1
1953 1
1954 1
1956 1
1957 2
1964 1
1967 1
1968 1
1969 1
1971 1
1972 1
1973 1
1976 2
1977 3
1978 3
1979 1
1981 1
1982 1
1983 2
1984 2
1985 2
1986 1
1987 1
1988 1
1989 1
1990 4
1991 1
1992 2
1993 2
1994 1
1995 1
1996 1
1999 1
2000 1
2001 2
2002 1
2003 3
2004 3
2005 3
2006 4
2007 3
2008 7
2009 5
2010 5
2011 3
2012 5
2013 11
2014 9
2015 10
2016 8
2017 13
2018 12
2019 15
2020 37
2021 35
2022 19
2023 15
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

254 results

Results by year

Filters applied: . Clear all
Page 1
The evolutionary history of lethal metastatic prostate cancer.
Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, Brewer DS, Kallio HML, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC; ICGC Prostate Group; Neal DE, Cooper CS, Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, Bova GS. Gundem G, et al. Among authors: whitaker hc. Nature. 2015 Apr 16;520(7547):353-357. doi: 10.1038/nature14347. Epub 2015 Apr 1. Nature. 2015. PMID: 25830880 Free PMC article.
ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression.
Scott E, Archer Goode E, Garnham R, Hodgson K, Orozco-Moreno M, Turner H, Livermore K, Putri Nangkana K, Frame FM, Bermudez A, Jose Garcia Marques F, McClurg UL, Wilson L, Thomas H, Buskin A, Hepburn A, Duxfield A, Bastian K, Pye H, Arredondo HM, Hysenaj G, Heavey S, Stopka-Farooqui U, Haider A, Freeman A, Singh S, Johnston EW, Punwani S, Knight B, McCullagh P, McGrath J, Crundwell M, Harries L, Heer R, Maitland NJ, Whitaker H, Pitteri S, Troyer DA, Wang N, Elliott DJ, Drake RR, Munkley J. Scott E, et al. Among authors: whitaker h. J Pathol. 2023 Sep;261(1):71-84. doi: 10.1002/path.6152. Epub 2023 Aug 7. J Pathol. 2023. PMID: 37550801 Free article.
Prostate cancer biology & genomics.
Whitaker H, Tam JO, Connor MJ, Grey A. Whitaker H, et al. Transl Androl Urol. 2020 Jun;9(3):1481-1491. doi: 10.21037/tau.2019.07.17. Transl Androl Urol. 2020. PMID: 32676435 Free PMC article. Review.
History of aphasia: A broad overview.
Eling P, Whitaker H. Eling P, et al. Among authors: whitaker h. Handb Clin Neurol. 2022;185:3-24. doi: 10.1016/B978-0-12-823384-9.00017-7. Handb Clin Neurol. 2022. PMID: 35078608 Review.
Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023.
Kissling E, Maurel M, Emborg HD, Whitaker H, McMenamin J, Howard J, Trebbien R, Watson C, Findlay B, Pozo F, Bolt Botnen A, Harvey C, Rose A; European IVE group; Members of the European IVE group. Kissling E, et al. Among authors: whitaker h. Euro Surveill. 2023 May;28(21):2300116. doi: 10.2807/1560-7917.ES.2023.28.21.2300116. Euro Surveill. 2023. PMID: 37227299 Free PMC article.
Stroma in normal and cancer wound healing.
Huet E, Jaroz C, Nguyen HQ, Belkacemi Y, de la Taille A, Stavrinides V, Whitaker H. Huet E, et al. Among authors: whitaker h. FEBS J. 2019 Aug;286(15):2909-2920. doi: 10.1111/febs.14842. Epub 2019 Apr 15. FEBS J. 2019. PMID: 30958920 Free article. Review.
The oncological relevance of fragile sites in cancer.
Simpson BS, Pye H, Whitaker HC. Simpson BS, et al. Among authors: whitaker hc. Commun Biol. 2021 May 12;4(1):567. doi: 10.1038/s42003-021-02020-5. Commun Biol. 2021. PMID: 33980983 Free PMC article. Review.
Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth.
Scott E, Hodgson K, Calle B, Turner H, Cheung K, Bermudez A, Marques FJG, Pye H, Yo EC, Islam K, Oo HZ, McClurg UL, Wilson L, Thomas H, Frame FM, Orozco-Moreno M, Bastian K, Arredondo HM, Roustan C, Gray MA, Kelly L, Tolson A, Mellor E, Hysenaj G, Goode EA, Garnham R, Duxfield A, Heavey S, Stopka-Farooqui U, Haider A, Freeman A, Singh S, Johnston EW, Punwani S, Knight B, McCullagh P, McGrath J, Crundwell M, Harries L, Bogdan D, Westaby D, Fowler G, Flohr P, Yuan W, Sharp A, de Bono J, Maitland NJ, Wisnovsky S, Bertozzi CR, Heer R, Guerrero RH, Daugaard M, Leivo J, Whitaker H, Pitteri S, Wang N, Elliott DJ, Schumann B, Munkley J. Scott E, et al. Among authors: whitaker h. Oncogene. 2023 Mar;42(12):926-937. doi: 10.1038/s41388-023-02604-x. Epub 2023 Feb 1. Oncogene. 2023. PMID: 36725887 Free PMC article.
PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.
Luszczak S, Kumar C, Sathyadevan VK, Simpson BS, Gately KA, Whitaker HC, Heavey S. Luszczak S, et al. Among authors: whitaker hc. Signal Transduct Target Ther. 2020 Jan 31;5(1):7. doi: 10.1038/s41392-020-0109-y. Signal Transduct Target Ther. 2020. PMID: 32296034 Free PMC article. Review.
254 results